echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > CStone's multispecific antibody CS2006/NM21-1480 China clinical trial application approved

    CStone's multispecific antibody CS2006/NM21-1480 China clinical trial application approved

    • Last Update: 2021-09-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    CStone Pharmaceuticals announced on September 15 that the clinical trial application of the multispecific antibody CS2006/NM21-1480 in China was approved by the China National Medical Products Administration
    .

    CS2006/NM21-1480 is a monovalent trispecific antibody targeting PD-L1, 4-1BB and human serum albumin (HSA)
    .


    According to its molecular design, CS2006/NM21-1480 can only conditionally induce the immune costimulatory receptor 4-1BB and activate anti-cancer T cells when combined with the immune checkpoint ligand PD-L1 on the surface of tumor cells.


    Compared with other PD-L1/4-1BB bispecific candidate antibodies, CS2006/NM21-1480's unique monovalent structure design and ultra-high affinity for PD-L1 will enable the dual effects of PD-L1 and 4-1BB in the tumor.
    Maximize the potential of the drug while avoiding systemic toxicity
    .


    In addition, the half-life can be extended by combining HSA


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.